{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018688","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.655146+00:00","generated_at":"2026-06-08T05:22:58.104250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Virios Q3 net loss narrows to $1.2M; secures FDA guidance for IMC-1 Phase 3","bullets":["Net loss $1.2M ($0.06/share) vs $2.6M ($0.28/share) in Q3 2022; cash $4.8M.","R&D expenses fell to $0.4M from $1.6M on lower clinical trial costs.","FDA guidance secured for IMC-1 Phase 3 in fibromyalgia; partnership discussions underway.","Briefing materials submitted to FDA for IMC-2 IND to treat Long-COVID.","Cash runway expected into Q3 2024 through expense management."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018688","json":"https://secwatch.observer/filing/0001558370-23-018688.json","markdown":"https://secwatch.observer/filing/0001558370-23-018688.md","text":"https://secwatch.observer/filing/0001558370-23-018688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/0001558370-23-018688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/tmb-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:22:58.104250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67f27c6ab566c2764a592a52b6361a9749308950","claim":"Dogwood Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $1.2 million, or $0.06 basic and diluted net loss per share, EPS $0.06 basic and diluted net loss per share.","evidence_excerpt":"On November 13, 2023, Virios Therapeutics, Inc. (the “Company”) issued a press release announcing the results of operations for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837023018688/0001558370-23-018688-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$1.2 million, or $0.06 basic and diluted net loss per share"},{"label":"EPS","value":"$0.06 basic and diluted net loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}